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Abstract
Background: The discovery of genetic associations is an important factor in the understanding of human illness to
derive disease pathways. Identifying multiple interacting genetic mutations associated with disease remains
challenging in studying the etiology of complex diseases. And although recently new single nucleotide
polymorphisms (SNPs) at genes implicated in immune response, cholesterol/lipid metabolism, and cell membrane
processes have been confirmed by genome-wide association studies (GWAS) to be associated with late-onset
Alzheimer’s disease (LOAD), a percentage of AD heritability continues to be unexplained. We try to find other
genetic variants that may influence LOAD risk utilizing data mining methods.
Methods: Two different approaches were devised to select SNPs associated with LOAD in a publicly available
GWAS data set consisting of three cohorts. In both approaches, single-locus analysis (logistic regression) was
conducted to filter the data with a less conservative p-value than the Bonferroni threshold; this resulted in a subset
of SNPs used next in multi-locus analysis (random forest (RF)). In the second approach, we took into account prior
biological knowledge, and performed sample stratification and linkage disequilibrium (LD) in addition to logistic
regression analysis to preselect loci to input into the RF classifier construction step.
Results: The first approach gave 199 SNPs mostly associated with genes in calcium signaling, cell adhesion,
endocytosis, immune response, and synaptic function. These SNPs together with APOE and GAB2 SNPs formed a
predictive subset for LOAD status with an average error of 9.8% using 10-fold cross validation (CV) in RF modeling.
Nineteen variants in LD with ST5, TRPC1, ATG10, ANO3, NDUFA12, and NISCH respectively, genes linked directly or
indirectly with neurobiology, were identified with the second approach. These variants were part of a model that
included APOE and GAB2 SNPs to predict LOAD risk which produced a 10-fold CV average error of 17.5% in the
classification modeling.
Conclusions: With the two proposed approaches, we identified a large subset of SNPs in genes mostly clustered
around specific pathways/functions and a smaller set of SNPs, within or in proximity to five genes not previously
reported, that may be relevant for the prediction/understanding of AD.
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Background
It is predicted the number of people who suffer from
Alzheimer’s disease (AD) will increase from 5 million to
13.4 million in the United States of America and will be
115.4 million worldwide by 2050 [1,2]. There is cur-
rently no treatment to stop or reverse the progress of
this disease. This neurodegenerative disorder is believed
to be caused by an inability to clear b-amyloid (increas-
ing all its forms: monomer, oligomer, insoluble fibrils,
and plaques) from the Central Nervous System provok-
ing neuronal impairment and cell death, and by tangled
tau formation when cells are dying [3]. Genetic variation
is an important contributor to the risk for this disease,
estimated to be up to seventy-nine percent in the late-
onset AD (LOAD) more frequent form of the disease
[4]. A few genes have been confirmed by independent
studies to be implicated with LOAD, summarized below.
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Alzheimer’s can be divided into early-onset AD
(EOAD) and LOAD. There are thus far three established
genes involved in EOAD and follow autosomal domi-
nant inheritance APP (b-amyloid precursor protein),
PSEN1 and PSEN2 (presenilin-dependent g-secretase
activity cuts amyloid precursor proteins into b-amyloid
peptides) [5,6]. Another well established genetic risk fac-
tor is APOE (it encodes a lipoprotein that may interact
with accumulated b-amyloid); it manifests in the more
common LOAD and its inheritance does not follow
Mendelian principles [7,8]. APOE has three common
alleles, ε4, ε3, and ε2, and each of these variants of the
gene are determined by two single nucleotide poly-
morphisms (SNPs). In European populations, ε4ε4
homozygotes are the most likely to develop disease, fol-
lowed by ε3ε4 heterozygotes and ε3ε3 homozygotes,
with ε2 heterozygotes having the least risk [8,9]. How-
ever, a person who has one or two copies of ε4 may
never develop AD, while another who does not carry
the ε4 alleles may [8].
APOE genotypes could be useful in combination with
other genetic variations to predict disease risk since the
scientific literature suggests the existence of additional
genetic factors associated with LOAD. In the past two
years, at least eight genes mapped to the immune sys-
tem, cholesterol metabolism, and cell membrane pro-
cesses have been confirmed by independent genome-
wide association studies (GWAS) to be implicated with
LOAD (See AlzGene database [10]). The genetic factors
are CLU (it encodes apoliprotein J and may have a simi-
lar function as to that of APOE), PICALM (it encodes a
protein involved in intracellular traffic of neurotransmit-
ters between proteins and lipids), CR1 (it encodes the
main receptor of complement C3b protein thought to
be involved in b-amyloid clearance through phagocyto-
sis) [5,11,12], BIN1 (it is involved in synaptic vesicle
endocytocis) [5,13,14]; moreover, recently two separate
studies conducted by Hollingworth P., et al and Naj, A.
C. et al identified MS4A6A/MS4A4E (these encode cell
membrane proteins), CD2AP (encodes a protein
involved in endocytocis), EPHA1 (it produces a mem-
brane bound protein involved in cell and axon guidance
and synaptic function; additionally, it is involved in cell
morphology, motility, and inflammation), and provided
further support for CD33 (it is involved in cell-cell
interaction and function regulation of cells in the
immune system and also mediates endocytocis through
a process independent from clathrin) [14,15]. Different
SNPs in CD33 were previously identified by Bertram, L.
et al [14-16]. CLU, PICALM, CR1 and BIN1 were con-
firmed by Naj, A.C. et al and BIN1 and CR1 were con-
firmed by Hollingworth P., et al as LOAD susceptibility
loci [14,15]. In the study by Naj, A.C. et al, the genetic
effect for the most salient SNPs at each locus had
estimated population attributable fractions (PAF) of
2.72% - 5.97%; nonetheless, the authors caution that the
true PAF might be different [15]. These newly con-
firmed genes could be mapped to pathways related to
the innate and adaptive immune response - (CLU, CR1,
CD33, EPHA1) [14,17], cell membrane processes includ-
ing endocytocis (PICALM, BIN1, CD33, CD2AP) [14],
and cholesterol/lipid metabolism (CLU) [14,17].
A few years ago, another gene that was shown to have
an increased associated risk with LOAD was GAB2
although with inconsistent reproducibility by indepen-
dent GWAS [18,19]. GAB2 protein may be involved in
protection from the formation of insoluble tau deposits
known as neurofibrillary tangles (NFTs) [9] and may
participate in the production of b-amyloid [20]. Reiman,
Eric. M. et al utilized stratification and linkage disequili-
brium (LD) analysis and found six SNPs, part of a com-
mon haplotype block covering the GAB2 gene, to have a
strong interaction with APOE in three groups of APOE
ε4 carriers [9].
APOE by itself, or in combination with GAB2, remains
to some extend a weak predictor for the risk of develop-
ing AD [8]. We used a published GWAS data set from
Reiman and colleagues [9] to analyze it for AD risk
determination in new loci by different models in APOE
ε4 positive and negative samples.
One of the challenges trying to identify multiple inter-
acting genetic mutations associated with disease in
studying the etiology of complex diseases arises from
the fact that there are millions of genome-wide variants,
many of them untyped in the study samples of GWAS,
and the number of possible combinations encountered
in “interaction analysis” grows exponentially with the
number of variants. As a result, it is computationally
prohibitive to perform a comprehensive test for interac-
tion analysis between four or more factors and disease.
Heuristic approaches must be developed to analyze
these data, that leverage and combined statistical and
data mining methods [21].
We devised two informatics approaches to identify
new genetic biomarkers. The first approach utilizes sta-
tistical and data mining methods. The second approach
also leverages prior biological knowledge to refine the
analysis. In both approaches, multi-locus (classifier
building) analysis is done with a reduced number of var-
iants that first passed, for instance, a single-locus (logis-
tic regression) threshold.
Results and discussion
Approach I: Choice of SNPs without prior biological
knowledge for model building
Step 1
In order to cast a wide net to filter the data and take
into account the correlation among some of the SNPs
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due to LD, the association analysis was run with a p-
value = 1E-3. SNPs from APOE and GAB2 were
excluded from the analysis, since these are already
known to be associated with AD in this data set [9].
This gave 199 SNPs with p-values ≤ 1E-3 and 1 < ORs
< 5. Table 1 lists the top seven scoring SNPs; the com-
plete list of all 199 SNPs is found in additional file 1,
table SA.
Step 2
After univariate association analysis, the Random Forest
(RF) classifier performance assessment was done with
the 199 SNPs data. With 100 trees, Figure 1 shows the
test and out of bag (OOB) errors for different number
of features (SNPs). The figure suggests that increasing
the number of attributes above 70 actually leads to a
gradual increase in test error rate, 10-fold cross valida-
tion (CV), for the 199 SNPs and APOE SNP and the
199 SNPs, APOE SNP and GAB2 SNPs sets. OOB error
rate (estimated class ŷi is determined from models
where row i is out-of- bag) is not a good estimation of
test error in all instances here; however, as features are
added to the forest the OOB error becomes a better
estimator of the test error for these two data sets. Figure
2 shows the classifier tuning; the additional induced ran-
domness on the selection of number of attributes for
choosing the splits seems to have worked, giving a mod-
est improvement with average 10-fold CV error rates in
the range of 23-27%.
In order to further improve the classifiers, a super-
vised instance resample filter was applied to the data.
The original case-control distribution in the data is 61%
cases and 39% controls. After the data is filtered the dis-
tribution of the data becomes 52% cases and 48% con-
trols. A big reduction in misclassification was obtained
by first resampling the data to make its distribution
more balanced followed by RF. The results at 100, 300,
and 600 trees and various numbers of attributes are
listed in Table 2. When APOE and GAB2 SNPs alone
are used, the average classification error rate is 33.3%.
This error rate is reduced when the 199 SNPs are used
for classification. Random forests built with eighteen
SNPs from the 199 SNPs give an average 10-fold CV
error of 11.7%, and when the 199 SNPs are added to the
bag containing either an APOE SNP or an APOE SNP
and GAB2 SNPs the average 10-fold CV error is
reduced to between 9.3% and 9.5% for 11 and 18 attri-
butes respectively.
A manual compilation of pathway, disease association,
or biological function information reveals some of the
199 SNPs are associated with genes involved in calcium
signalling, cell adhesion, endocytosis, and immune
response in addition to synaptic function. This informa-
tion was added to both Table 1 and the additional file 1,
Table 1 Logistic regression top scoring SNPs, approach I
Gene Symbol dbSNP
RS ID
Distance to
Gene
Unadj. p-
value
FDR_BH p-
value
OR (95%
CI)
Pathway/Disease/function
NISCH rs6784615 intron 7.16E-07 4.47E-02 2.21 (1.61-
3.02)
Interaction with PAK4 for reduction of LIMK1
phosphorylation;
neuronal migration and axon/dendrite outgrowth
[22,23].
RABEP1 rs4356530 upstream 27742 8.59E-07 4.47E-02 2.21 (1.61-
3.02)
Endocytosis [24,32].
THEMIS rs9398855 intron 2.25E-06 8.78E-02 2.13 (1.56-
2.92)
Immnune response [25-27].
NDUFA12
rs249153
downstream
40719
4.13E-06 1.29E-01 1.62 (1.32-
2.00)
AD, Parkinson’s, Hungtinton’s, oxidative
phosphorylation [28-32].
MUC21 rs2517509 downstream
72544
4.93E-06 1.39E-01 3.14 (1.92-
5.12)
Prevention of cell-cell interaction of Integrins [55].
TUSC1 rs10115381 upstream 328744 5.33E-06 1.39E-01 2.08 (1.52-
2.85)
Shwachman-Diamond syndrome [56].
CTNNA3 rs10996618 downstream
187123
1.19E-05 2.03E-01 2.03 (1.48-
2.78)
AD (4 studies), Adherens junction, Inmune response
[10,32].
FDR_BH = Benjamini & Hochberg (1995) step-up False Discovery Rate control.
Figure 1 RF performance assessment, different number of
features and number of trees fixed at 100; approach I.
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table SA. Some of the genes linked to the 199 SNPs
appear among genes previously identified in GWAS as
posted in the AlzGene database [10]. Furthermore, some
of the top 199 SNPs are novel SNPs part of or in proxi-
mity (may be acting as flags) to genes that may be
engaged in a cascade of events leading to AD. Some of
these genes and their relevance to AD are discussed
below.
For instance, NISCH codes for a cytosolic protein
Nischarin which negatively affects cell migration by
forming inhibitory complexes with PAK family kinases
among other proteins [22]. PAK4 suppression decreases
the phosphorylation of LIMK1, key for axon/dendrite
outgrowth and neuronal migration [23]. Another gene,
RABEP1 codes for rabaptin-1 which interacts with Gap-
43. One of the main roles of Gap-43 is adjustment of
neurotransmitter release, endocytosis, and long-term
potentiation and its expression and function is altered in
AD [24]. Recently identified THEMIS produces a protein
also known as GAB2 associated protein (Gasp) which
plays a crucial regulatory role in positive selection dur-
ing thymocyte development [25-27]. Post-positive selec-
tion, thymocytes differentiate into CD4 or CD8 single-
positive (SP) thymocytes as determined by their restric-
tion to MHC class II and I respectively. SP CD4 and
CD8 in time leave the thymus for other organs and
form part of the adaptive immune system. It is thought
Gasp may function through a new molecular pathway
downstream of T-cell receptor (TCR) signalling [27].
Further studies will be needed to establish the role this
gene may play in the etiology of AD.
Changes of the expression of mitochondrial genes
such as NDUFA12, part of complex I, may alter the oxi-
dative metabolism in AD [28,29]. Complex I initiates
electron transfer by oxidizing NADH and transferring
the electrons to coenzyme Q while pumping protons
across the mitochondrial membrane creating an electro-
chemical proton gradient [29]. The high rate of oxygen
consumption needed for normal function, polyunsatu-
rated fatty acid and transition metal ion composition,
and limited antioxidant defence mechanisms renders
neurons vulnerable to oxidative damage [29,30]. Energy
decline and mitochondrial dysfunction are a major, early
event in AD. Complex I deficiency decreases energy
production by oxidative phosphorylation this in turn
Figure 2 RF tuning, best number of attributes at different
number of trees; approach I. F = number of features.
Table 2 RF modeling, filtered data, approach I
Data RF 10-Fold CV % Error
(APOE ε4+ & ε4- samples) Number of Trees F = 7 F = 11 F = 18 F = 32 F = 42
APOE & 10 GAB2 SNPs
100 33.3 33.2
300 33.3 33.2
600 33.4 33.5
199 SNPs
100 11.9 12.3 12.5 12.3
300 11.3 11.3 12.1 11.6
600 10.6 11.6 11.2 11.1
APOE & 199 SNPs
100 10.9 9.9 10.4 10.3
300 8.9 9.6 9.5 10.3
600 9.0 9.1 10.1 9.9
APOE, 10 GAB2, & 199 SNPs
100 9.9 10.1 9.9 11.2
300 8.9 9.1 9.5 10.3
600 9.1 9.4 9.9 10.3
F = number of features.
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increases reactive oxygen species (ROS) which often
causes structural and functional cell membrane changes
setting off a vicious cycle that ends in apoptosis.
Research by Rhein et al found tau induces mitochon-
drial dysfunction and increases levels of ROS and
together with b-amyloid synergistically alters complex I
function and energy balance with aging in AD [31]. Tau
has specific sensitivity of complex I oxidative phosphor-
ylation system. Furthermore, b-amyloid directly interacts
with mitochondria via the translocase of the outer mem-
brane (TOM) system. Additionally, maternal family his-
tory of AD links maternal inheritance of mitochondria
to predisposition to AD and glucose hypometabolism
[31]. NDUFA12 is already listed as part of the AD path-
way [32].
Approach II: Choice of SNPs with prior biological
knowledge for model building
Step 1
Table 3 highlights 19 SNPs with the smallest p-values
from the logistic regression and stratified analysis, in
strong LD, and within six genes potentially relevant to
AD. The LD patterns and gene overlays for the SNPs
are shown in the supplementary information (additional
file 2, figure S1, additional file 3, figure S2, additional
file 4, figure S3, additional file 5, figure S4, additional
file 6, figure S5, and additional file 7, figure S6).
Four genes, distinct from the ones already identified in
approach I, are discussed next.ST5, suppression of
tumorigenicity 5, encodes three proteins. One of the
proteins, p126, is an activator of mitogen-activated pro-
tein kinase MAPK1 also known as ERK2 [33]. ERK1 and
ERK2 are some of several proline-directed kinases that
have been shown to phosphorylate tau protein [34]. Tau
binds and stabilizes microtubules in cells and in neu-
rons; intracellular transport occurs in axons through
microtubules [35]. Hyperphosphorylation reduces tau
binding to microtubules and may increase neurofibril-
lary tangles (NFTs) in cell bodies and dendrites of neu-
rons [36]. There is direct correlation between NFTs and
memory decline in AD patients [36]; however, it
remains to be seen how important of a role ERK2 plays
in the hyperphosphorylation of tau. Another gene,
TRPC1 codes for a TRP cation channel protein
expressed in the neurons of the hippocampus and cor-
tex among other regions of the brain. TRPC1 is acti-
vated by either G receptor proteins or intracellular Ca2+
depletion [37]. Strübing et al discovered that TRPC1
channels uniquely adjust neuronal function indepen-
dently of synapse processes [37]. In addition, they
demonstrated that TRPC1 can form heteromeric chan-
nels i.e. TRPC1/TRPC5. TRPC5 is expressed in the hip-
pocampus; TRPC1/TRPC5 is activated by Gq-coupled
receptors and not by Ca2+ depletion and its regulation is
not neurotransmitter specific [37]. Calcium signalling
necessary for axonal regeneration in the adult CNS and
for growth cone response of spinal neurons in Xenopus
to myelin-associated glycoprotein is mediated by TRPC1
channels [38]. Calcium disequilibrium has been observed
to lead to neuronal injury and apoptosis [39]. Key mod-
ulators of calcium homeostasis such as presenilins and
CALHM1 have been associated with EOAD [39]; how-
ever, there have not been prior studies on TRPC1 in AD
patients.
ATG10 is an E2-like ligase protein involved in two
ubiquitin-like modifications essential for autophagosome
formation [40]. Autophagy is an intracellular degrada-
tion mechanism responsible for clearance of misfolded
proteins, pathogens, and organelles (organelles such as
functionally disabled mitochondria in aging) [41]. Dou-
ble-membrane autophagosomes enclose cytoplasmic
proteins and later degrade them by fusing with lyso-
somes. Autophagy initiation enhances the clearance of
tau and offers a cytoprotective role. Overactive or dys-
functional autophagy may promote neuronal cell death
in disease states contributing to the pathology of multi-
ple neurodegenerative disorders [42]. Blocking autopha-
gosome formation by knockout of either ATG5 or
ATG7 genes causes ubiquitinated protein aggregates and
eventual neurodegeneration, demonstrating that autop-
hagy is both constitutive and essential for neuronal
functioning [42].
A genome-wide screen study by Lipinski et al showed
that ROS are common mediators upstream of the acti-
vation of the type III PI3 kinase (critical protein in
autophagy initiation) in response to b-amyloid peptide.
On the other hand, lysosomal blockage also caused by
b-amyloid is independent of ROS. Furthermore, they
proved that autophagy is transcriptionally down-regu-
lated during normal aging in the human brain in con-
trast to the autophagy up-regulation observed in later
stages of AD human brains. In addition, AD drugs they
tested have inhibitory effects on autophagy, decreasing
input into the lysosomal system; they hypothesized this
may ameliorate cellular stress in AD [43].
A fourth gene, ANO3 encodes anoctamin 3, rs1389421
is in a 49 kb LD region upstream of ANO3 as seen in
additional file 5, figure S4. The anoctamin family of ten
highly hydrophobic membrane proteins is also known as
TMEM16 [44]. Some anoctamins function as Ca2+ acti-
vated Cl- channels (CaCCs) in the retinal photoreceptor
synaptic terminals and the olfactory sensory neurons;
others participate in tumor progression [44,45]. Some
studies indicate that olfactory neurogenesis disruption is
linked to AD [46]. ANO2, 3, and 4 are mostly expressed
in neuronal tissues. ANO3 and ANO4 mRNA are equally
expressed in spinal cord, brain stem, cerebellum, and
eye; however, it is not known how ano3 and ano4
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function thus far [44,47]. Ist2p, ANO in S. cerevisiae, is
translated locally at the peripheral endoplasmic reticu-
lum (ER) and may be inserted into the plasma mem-
brane by the fusion of peripheral ER with the plasma
membrane. If these anion selective proteins in mammals
are transported by a similar novel mechanism, it is
believed they might have effects in protein synthesis in
axons and dendrites [45].
Step 2
The 19 SNPs in LD with six genes that resulted from
the analysis in step 1 above were used next in RF. Table
4 shows that when combining the 19 SNPs with the
APOE SNP the average 10-fold CV error rate is reduced
to 20.5%. The 10-fold CV error rate is reduced to 16.9%
when the data set is the 19 SNPs, APOE SNP, and 10
GAB2 SNPs, and using 600 trees and 11 features for
tree building. The higher 10-fold CV error rate obtained
in approach II as compared to that of approach I may
not be due to LD. As Meng, Y.A. et al explain, in RF if
a SNP is near the root of a tree in the forest and a sec-
ond SNP in LD with the first SNP is close to the leaf of
the same tree, the permutation of the first SNP value
will not increment the prediction error of the tree
because the second SNP can be a substitute for the first
SNP. However, the prediction error might be still some-
what increased [48].
Conclusions
It is believed that LOAD is a complex disease caused by
the interaction of multiple genetic and environmental
factors. In the past two years, at least eight genes have
been confirmed to be associated with LOAD. These are
common risk variants of moderate to small effects the
same as APOE. The new variants functionality could be
mapped to the immune response, cholesterol metabo-
lism, and cell membrane processes pathways [14].
Table 3 CMH top scoring SNPs in LD, approach II.
Gene (Chr.) dbSNP RS ID Physical Position Distance to Gene Minor Allele (MAF) p-value from c2 OR (95% CI)
APOE ε4- SAMPLES
ST5 (11)
rs4910068 8830651 intron C (0.25) 9.47E-05 1.57 (1.25-1.98)
rs10743089 8744744 intron A (0.33) 2.12E-05 1.59 (1.28-1.97)
APOE ε4+ SAMPLES
TRPC1 (3)
rs4259003 144006245 intron A (0.21) 6.82E-05 2.36 (1.53-3.64)
rs9784320 144024724 intron C (0.25) 9.68E-04 1.87 (1.28-2.71)
rs2033912 143999057 intron T (0.22) 1.71E-03 1.86 (1.26-2.75)
rs891159 81526843 intron C (0.24) 2.40E-05 2.34 (1.56-3.49)
ATG10 (5)
rs1485587 81362798 intron G (0.48) 8.11E-05 1.82 (1.35-2.45)
rs4703879 81589571 intron A (0.24) 1.01E-03 1.86 (1.28-2.71)
ANO3 (11)
rs1389421 25747721 upstream 561825 G (0.45) 3.39E-06 2.07 (1.52-2.83)
rs10834774 25715397 upstream 594149 C (0.20) 4.01E-03 1.86 (1.21-2.85)
rs11028909 25729021 upstream 580525 G (0.20) 4.13E-03 1.84 (1.21-2.81)
NDUFA12 (12)
rs249153 93848520 downstream 40719 C (0.19) 3.19E-06 1.63 (1.33-2.00)
rs249154 93848687 downstream 40552 C (0.18) 3.22E-05 1.54 (1.25-1.89)
APOE ε4+ and ε4- SAMPLES
NISCH (3)
rs6784615 52481466 intron C (0.09) 6.63E-07 2.13 (1.57-2.88)
rs9855470 52468315 intron A (0.06) 4.86E-05 2.11 (1.46-3.05)
rs6445486 52481531 intron A (0.06) 2.77E-04 1.90 (1.34-2.71)
rs10865972 52466487 intron C (0.06) 3.38E-04 1.87 (1.32-2.65)
rs4687619 52493826 intron T (0.06) 3.54E-04 1.93 (1.34-2.79)
rs6810027 52499614 intron C (0.05) 5.80E-04 1.89 (1.31-2.73)
All p-values are uncorrected.
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However, a percentage of AD heritability is still missing.
The purpose of this study was to explore new associa-
tions between multiple SNPs and AD by data mining
approaches. We analyzed a published AD GWAS data
set by a couple of two-step approaches that first filtered
the data with a low threshold to obtain a data subset
used in a second step for multi-locus analysis. In one
approach statistical and data mining techniques were
implemented, and in the other approach biological
domain knowledge and LD analysis were done prior to
the multi-locus analysis. A 10-fold CV was done with
the multi-locus analysis which helped remove bias from
the reported error rate. Previously AD associated SNPs
[7,9] were removed from the data to avoid obscuring
other possible significant variants. There is overlap
between the SNPs identified with both approaches;
some of the genes associated with the SNPs used to
build the classifiers have not been reported before as
currently listed in the AlzGene database [10].
The model built for approach I confirmed, that APOE
and GAB2 genotypes alone can produce a moderate
determinant of LOAD status [9], being able to discrimi-
nate between cases and controls with about 33% error
rate (10 fold CV). By adding close to 200 other genome-
wide SNPs that had a relatively high score of association
with LOAD from the GWAS data set, the error rate of
the model was greatly reduced, from 33% to about 10%.
While many of the 200 SNPs were in the vicinity of
genes that could potentially be involved in AD path-
ways, some of them were not.
The model built for approach II leveraged biological
domain knowledge to select a small number of SNPs
from genes that had relevance to LOAD. This model
used only 19 to 30 SNPs (Table 4), while the model in
Table 4 RF modeling, filtered data, approach II.
Data RF 10-Fold Cross Validation % Error
(APOE ε4+ and ε4- samples) Number of Trees F = 6 F = 7 F = 11 F = 18
APOE & 10 GAB2 SNPs
100 33.3 33.2
150 33.4 33.5
200 33.4 33.2
250 33.2 33.2
300 33.3 33.2
600 33.4 33.5
19 SNPs
100 26.9 27.5 27.9
150 26.7 27.0 27.5
200 26.8 27.0 27.4
250 27.1 27.3 27.6
300 27.2 27.1 27.6
600 27.1 27.4 27.4
APOE & 19 SNPs
100 20.3 20.8 20.7
150 19.9 20.6 20.8
200 20.1 20.7 20.9
250 20.3 20.6 20.6
300 20.1 20.6 20.6
600 19.8 20.4 20.7
APOE, 10 GAB2, & 19 SNPs
100 17.6 17.6 18.2
150 17.2 17.0 17.6
200 17.2 17.2 18.1
250 17.3 17.1 17.9
300 17.2 17.3 17.9
600 17.3 16.9 17.6
F = number of features
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approach I used one order of magnitude more, about
200 SNPs (Table 2). The model in approach II was less
successful in lowering the LOAD classification error rate
- to only about 17%, vs. the 10% that the model in
approach I did. Approach II; however, with its limited
number of biologically-relevant SNPs, would be much
easier to test, as opposed to the model in approach I,
which included 200 genome-wide SNPs. A model
employing dozens of SNPs might be harder to test, but
it could be that dozens of genetic variants linked to
many different pathways could be involved in the etiol-
ogy of AD as is the case for other complex diseases
[19], and as it is beginning to emerge from the GWAS
outcomes from the past two years.
In order to improve the results from the analysis of
this data, a (joint) meta-analysis could be done with
another AD data set conducted on the same platform.
The combined data sets would give more statistical
power for gene-gene interaction effects and make pos-
sible fine mapping of variants with larger effect sizes.
The functionality of the selected SNPs here could be
further assessed by mapping the variants to genes that
interact with or are in the same pathways as those
already implicated in AD, and querying of genomic
annotations of SNPs representing variation in micro-
RNA target sites.
The two approaches described here are only a starting
point that can be further refined to better understand
the possible causes of LOAD. Similar approaches - that
combine high throughput genomics techniques, statisti-
cal and data mining analysis, and leverage biological
domain knowledge - can be applied to study other com-
plex diseases that have a strong genetic component.
Methods
Data
A published AD GWAS data set was obtained from the
Translational Genomics Research Institute [9]. The data
includes results on 312,316 SNPs that passed quality
control checks across the genome genotyped with the
Mapping 500K Array set from Affymetrix on 1411
LOAD cases and controls from a discovery group and
two replicate groups. Each of the three groups is divided
into two sub-groups of APOE ε4 carriers and ε4 non-
carriers. In addition to genotypes, the original data
includes phenotypes such as gender, age of disease
onset, and age at death. The analysis presented here
focuses on genotype interactions and excludes these
phenotypes from the analysis.
The data can be described as 312,316 nominal predic-
tors along with a two class response variable y. The
response variable is unevenly distributed; it is 61% cases
and 39% controls. Also, the data has missing values.
Furthermore, in order to avoid false-positive results due
to population stratification, the data is from a Caucasian
population of European ancestry; the samples were
obtained from the United States and from the
Netherlands.
The data was originally used to identify a novel inter-
action between LOAD and two genes, APOE and GAB2
[9]. In this analysis, known GAB2 and APOE SNPs are
first excluded and then re-added in the model building
phase. In the next section, we describe the approaches
employed and briefly explain the RF algorithm.
Analytical approaches for Alzheimer’s disease association
analysis
In order to identify new genetic variants that increase
disease risk, we implement some of the latest algorithm
versions for disease association, LD, and data mining
with the most recent genetic variant annotation files. A
two step analysis, to reduce multiple genetic interactions
to be tested, is implemented by two approaches: one
statistically driven and a second incorporating sample
stratification and biological knowledge. In the first step
of both approaches, SNPs are filtered at a less stringent
threshold for disease association. The multiple testing
threshold correction, Bonferroni, assumes there are M
independent tests (ap = ae /M where ap is the point-
wise error and ae is the experimental error); however,
the independence assumption fails in genetic association
studies since there is correlation among some of the
SNPs due to LD. Thus, we use a threshold of p-value =
1E-3 and take into account positive ORs (a positive OR
means the minor allele increases disease risk relative to
the major allele) for the genome-wide screening step.
Furthermore, for the first step of approach II, the data is
also filtered by the p-values and ORs from chi-square
tests, and by significant LD values of selected SNPs
within or close (~5 Kb) to neurobiological relevant
genes. For both two step methods, known GAB2 and
APOE SNPs (originally published with this data set [9])
are first removed so they do not obscure the finding of
other statistically significant SNPs and then they are re-
added in the RF building phase.
Random forest (or random forests) is an ensemble
classifier that consists of many decision trees and out-
puts the class that is the mode (most frequent outcome)
of the class’s output by individual trees [49]. Ensemble
methods use multiple models to obtain better predictive
performance than could be obtained from any of the
constituent models. For example, if individual classifiers
would have an error rate of ε = 0.35, an ensemble of
twenty-five independent base classifiers will make a
wrong prediction at a smaller rate of 0.06 by the for-
mula
∑25
i=13
(
25
i
)
i(1− )25−i = 0.06[50].
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RF is a special case of bagging algorithm which is sim-
ple to train and tune. Bagging, or bootstrap aggregating,
is a parallel ensemble method that induces additional
randomness by allowing bag size to be chosen [51]. For
each classifier in the ensemble, a sample is drawn uni-
formly and with replacement from the original training
data set. If the training data has more rows expressing
cases than expressing controls, the randomness causes
more frequent cases rows in the bag than control rows.
This results in cases rows getting classified much better
than the control rows. The aim is to have both classes
classified in a way to lead to overall low error rate. RF,
as a classifier, induces additional randomness in the
selection of features from a subset for deciding the splits
at the nodes in each tree and if the skewed features in
the data are de-selected one may improve the model
predictions or vice versa. The size of the subset is
decided by first taking the square root of the total num-
ber of attributes in the data set or by the log2 of the
total number of attributes + 1. The additional random-
ness in RF helps to reduce variance (correlation among
attributes) and maintain bias. It is standard to let the
trees grow deep and not to prune them since the aver-
age of trees that are put together is taken to reduce the
variance.
In the second step for both approaches, RF algorithms
are optimized to build stable classifiers with new SNPs,
the most significant APOE SNP (rs4420638) identified
by Coon et al [7], and 10 GAB2 SNPs (Table 1[9]) for
AD prognosis.
Approach I: Choice of SNPs without prior biological
knowledge for model building
Step 1
Logistic regression with a less stringent p-value than the
Bonferroni cut-off of 0.05/312,316 = 1.55E-7 is per-
formed using PLINK v 1.07 [52] on all samples. A filter
is set at a p-value = 1E-3 and the association analysis is
run with removal of APOE and GAB2 SNPs. In addition,
SNPs with p-values ≤ 1E-3 and 1 < ORs < 5 are
selected. The raw genotype data corresponding to each
of the selected SNPs is extracted by running Perl scripts
and PLINK code. And to identify the genes correspond-
ing to these SNPs, annotation files updated by the chip
manufacturer (Affymetrix) with the Human Genome v
19 are queried.
Step 2
After pre-formatting the data subset, the data mining
analysis is run using WEKA v 3-6-6 [53]. All the analy-
sis in this study involves a cross validation of 10 folds
without pruning the trees. To start the RF model build-
ing, the number of SNPs to include in the model is cal-
culated by taking the square root of the total number of
SNPs. Four data sets are used to build the RF classifiers,
and all of the sets have y (disease) in the last column as
class attribute. The first data set includes the APOE
SNP and 10 GAB2 SNPs, the second set consists of the
SNPs from step 1, the SNPs from step 1 plus the APOE
SNP form the third set, and the fourth set comprises
the SNPs from step 1, the APOE SNP, and 10 GAB2
SNPs. In order to assess the performance of each of the
classifiers, the number of trees is held constant at 100
and the number of features (SNPs) is varied. Then, the
classifiers are tuned by holding constant the various
numbers of attributes, which gave the smallest test and
OOB error rates (for the three data sets) in the perfor-
mance step, and by changing the number of trees.
A supervised instance resample filter is applied to
each data set. This produces a random subsample of
each data set using sampling with replacement. The fil-
ter is set to bias the class distribution towards a uniform
distribution; the original case-control distribution in the
data is 61% cases and 39% controls.
After classification modelling, a manual compilation of
epistasis information relevant to AD on the 199 SNPs is
done.
Approach II: Choice of SNPs with prior biological
knowledge for model building
Step 1
For the second approach, prior biological knowledge is
used to supplement statistical analysis in selecting SNPs
from genes that are more likely to play a role in AD.
SNPs from APOE and GAB2 are excluded; then, the
data is filtered by p-values ≤ 1E-3 and 1 < ORs < 5
from logistic regression and the Cochran-Mantel-Haens-
zel (CMH) test. For CMH, the stratification (three
groups) is done based on APOE ε4 carrier status using
PLINK.
A list of twenty-three SNPs selected from logistic
regression and CMH based on their p-values and ORs,
and situated in the vicinity of genes potentially relevant
to AD is uploaded into Haploview v 4.2 [54] in order to
find their linkage to other SNPs within a 300 kb region.
The default settings are kept; the “Download HapMap
info Track”, release 22 version 2 and release 21 with
panel CEU (Caucasian European), and the “Solid Spine”
method to detect strong LD are utilized [54].
Step 2
The RF is implemented at various fixed number of
attributes and trees with four different data sets. The
APOE SNP and 10 GAB2 SNPs are a first set, the
SNPs in LD from step 1 are a second set, and the
SNPs from step 1 together with the APOE SNP are a
third set. The SNPs from step 1 added to the APOE
SNP and GAB2 SNPs make a fourth set. The classifica-
tion building is performed in the same manner as for
approach I - step 2.
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Additional material
Additional file 1: Table SA. Complete list of 199 SNPs from logistic
regression approach I with corresponding pathway, disease or biological
function information which may be pertinent to AD.
Additional file 2: Figure S1. LD display for SNPs across the 300 kb
region surrounding the ST5 locus. Top: Entrez gene track overlaid with
Hapmap genotyped SNPs across a 300 kb pairs interval surrounding the
ST5 locus. Bottom: zoomed LD SNP region. The SNPs identified,
rs4910068 and rs10743089, were found to be in significant LD with a D’
value of 0.83. Standard color scheme for Haploview: D’ < 1 and LOD < 2
are white, D’ = 1 and LOD < 2 are blue, D’ < 1 and LOD ≥ 2 are shades
of pink/red, D’ = 1 and LOD ≥ 2 are bright red. LOD = log of the odds.
Additional file 3: Figure S2. LD display for SNPs across the 300 kb
region surrounding the TRPC1 locus. Top: Entrez gene track overlaid with
Hapmap genotyped SNPs across a 300 kb region surrounding the TRPC1
locus. Bottom two: zoomed LD SNP region. The SNPs identified,
rs4259003, rs9784320, and rs2033912, were found to be in significant LD;
rs4259003 and rs9784320, rs4259003 and rs2033912, and rs9784320 and
rs2033912 with D’ values of 1.0. Standard color scheme for Haploview: D’
< 1 and LOD < 2 are white, D’ = 1 and LOD < 2 are blue, D’ < 1 and
LOD ≥ 2 are shades of pink/red, D’ = 1 and LOD ≥ 2 are bright red. LOD
= log of the odds.
Additional file 4: Figure S3. LD display for SNPs across the 300 kb
region surrounding the ATG10 locus. Top: Entrez gene track overlaid with
Hapmap genotyped SNPs across a 300 kb region surrounding the ATG10
locus. Bottom three: zoomed LD SNP region. The SNPs identified,
rs891159, rs1485587, and rs4703879, were found to be in significant LD;
rs891159 and rs1485587, rs891159 and rs4703879, and rs1485587 and
rs4703879 with D’ = 1. Standard color scheme for Haploview: D’ < 1 and
LOD < 2 are white, D’ = 1 and LOD < 2 are blue, D’ < 1 and LOD ≥ 2
are shades of pink/red, D’ = 1 and LOD ≥ 2 are bright red. LOD = log of
the odds.
Additional file 5: Figure S4. LD display for SNPs across the 300 kb
region surrounding the ANO3 locus. Top: Entrez gene track overlaid with
Hapmap genotyped SNPs across a 300 kb region surrounding the ANO3
locus. Bottom two: zoomed LD SNP region. The SNPs identified,
rs1389421, rs10834774, and rs11028909, were found to be in significant
LD; rs1389421 and rs10834774, rs1389421 and rs10834774, and
rs11028909 and rs10834774 with D’ = 1. Standard color scheme for
Haploview: D’ < 1 and LOD < 2 are white, D’ = 1 and LOD < 2 are blue,
D’ < 1 and LOD ≥ 2 are shades of pink/red, D’ = 1 and LOD ≥ 2 are
bright red. LOD = log of the odds.
Additional file 6: Figure S5. LD display for SNPs across the 300 kb
region surrounding the NDUFA12 locus. Top: Entrez gene track overlaid
with Hapmap genotyped SNPs across a 300 kb pairs interval surrounding
the NDUFA12 locus. Bottom: zoomed LD SNP region. The SNPs identified,
rs249153 and rs249154, were found to be in significant LD with D’ = 1.
Standard color scheme for Haploview: D’ < 1 and LOD < 2 are white, D’
= 1 and LOD < 2 are blue, D’ < 1 and LOD ≥ 2 are shades of pink/red,
D’ = 1 and LOD ≥ 2 are bright red. LOD = log of the odds.
Additional file 7: Figure S6. LD display for SNPs across the 300 kb
region surrounding the NISCH locus. Top: Entrez gene track overlaid with
Hapmap genotyped SNPs across a 300 kb region surrounding the NISCH
locus. Bottom: zoomed LD SNP region. The SNPs identified, rs6784615,
rs9855470, rs6445486, rs10865972, rs4687619, and rs6810027, were found
to be in significant LD; rs6784615 and rs9855470, rs6784615 and
rs6445486, rs6784615 and rs10865972, rs6784615 and rs4687619,
rs6784615 and rs6810027, rs9855470 and rs6445486, rs9855470 and
rs10865972, rs9855470 and rs4687619, rs9855470 and rs6810027,
rs6445486 and rs10865972, rs6445486 and rs4687619, rs6445486 and
rs6810027, rs10865972 and rs4687619, rs10865972 and rs6810027, and
rs4687619 and rs6810027 with D’ values of 1. Standard color scheme for
Haploview: D’ < 1 and LOD < 2 are white, D’ = 1 and LOD < 2 are blue,
D’ < 1 and LOD ≥ 2 are shades of pink/red, D’ = 1 and LOD ≥ 2 are
bright red. LOD = log of the odds.
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